• Join
  • Login
  • Contact

Search abstracts

Oral absorption of peptides/oligonucleotides - how far have we come?

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: BRAYDEN, David (University College Dublin, Conway Institute, Dublin, Ireland)
  • Co-author(s): David Brayden: Conway Institute, University College Dublin, Dublin, Ireland
  • Abstract:

    Three oral peptide formulations have reached Phase III trials, with another   ̴20-25 technologies in Phase II.  Tarsa’s (NJ) oral salmon calcitonin (sCT) (TBRIA™) for osteoporosis was submitted in 2015 following a Phase III trial (ORACAL) and comprises an enteric-coated tablet/capsule with sCT and a peptidase inhibitor (citric acid) in vesicles. 


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses